Status:
COMPLETED
The Effect of Buprenorphine Delivered by Buprenorphine Transdermal System (BTDS) on QT Intervals in Healthy Volunteers
Lead Sponsor:
Purdue Pharma LP
Conditions:
Healthy Volunteers
Eligibility:
All Genders
18-55 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to examine the effect of buprenorphine on QT interval corrected for heart rate (QTc) in healthy subjects.
Detailed Description
Drugs in this opioid class have been associated with prolonging QT interval/QT interval corrected for heart rate (QTc).
Eligibility Criteria
Inclusion
- Males and females 18 to 55 years of age, inclusive.
- Body weight ranging from 50 to 100 kilograms (kg) and a body mass index (BMI) ≤ 30 kg/m2.
- Healthy as determined by unremarkable medical history, physical examination, vital signs, laboratory evaluations, electrocardiogram (ECG), and a 24-hour screening ECG telemetry.
- Willing to refrain from strenuous exercise or contact sports during the study.
- Female subjects must be surgically sterile or at least 2 years postmenopausal, or using an effective contraceptive method (intrauterine device, hormonal contraceptive, or double-barrier method).
Exclusion
- Any clinically significant illness during the 30 days prior to randomization.
- Any history of allergy to buprenorphine, any excipient of BTDS, opioids, psychotropic or hypnotic drugs, and/or moxifloxacin or any member of the quinolone class of drugs.
- A clinically significant history of allergic reaction to wound dressings or bandages.
- Any medical or surgical conditions which might interfere with drug absorption (transdermal or gastrointestinal), distribution, metabolism, or excretion.
- Abnormalities on physical examination, vital signs, ECG, or clinical laboratory values, unless those abnormalities are judged to be clinically insignificant by the Investigator.
- Any cardiovascular disorders, including hypertension.
- Oxygen saturation (SpO2) ≤ 94% as measured by pulse oximetry.
- Any personal or family history of prolonged QT interval or disorders of cardiac rhythm.
- Abnormal cardiac condition denoted by any of the following:
- QT interval ≥ 450 milliseconds (msec).
- PR interval \> 240 msec or ≤ 110 msec.
- Evidence of second- or third-degree atrioventricular (AV) block.
- Pathological Q-waves (defined as Q-wave \> 40 msec or depth \> 0.5 mV).
- Evidence of ventricular preexcitation, complete left bundle branch block, right bundle branch block (RBBB), or incomplete RBBB.
- A resting heart rate outside the range of 50 to 85 beats per minute (bpm).
- Other protocol-specific exclusion/inclusion criteria may apply.
Key Trial Info
Start Date :
July 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2004
Estimated Enrollment :
132 Patients enrolled
Trial Details
Trial ID
NCT01148537
Start Date
July 1 2004
End Date
December 1 2004
Last Update
September 3 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
PPD Development, LP, Clinics
Austin, Texas, United States, 78704